Lee Danner & Bass Inc. Invests $27,000 in Integer Holdings Co. (NYSE:ITGR)

Lee Danner & Bass Inc. acquired a new position in shares of Integer Holdings Co. (NYSE:ITGR) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 200 shares of the medical equipment provider’s stock, valued at approximately $27,000.

Several other institutional investors and hedge funds also recently modified their holdings of ITGR. HUB Investment Partners LLC bought a new stake in Integer during the fourth quarter worth about $219,000. Xponance Inc. raised its stake in Integer by 9.5% in the fourth quarter. Xponance Inc. now owns 2,396 shares of the medical equipment provider’s stock valued at $318,000 after buying an additional 207 shares during the period. Intech Investment Management LLC raised its stake in Integer by 51.1% in the fourth quarter. Intech Investment Management LLC now owns 11,767 shares of the medical equipment provider’s stock valued at $1,559,000 after buying an additional 3,980 shares during the period. Cibc World Markets Corp acquired a new position in shares of Integer in the fourth quarter valued at approximately $413,000. Finally, Corient Private Wealth LLC grew its position in shares of Integer by 6.4% in the fourth quarter. Corient Private Wealth LLC now owns 1,969 shares of the medical equipment provider’s stock valued at $261,000 after purchasing an additional 118 shares during the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Oppenheimer downgraded Integer from an “outperform” rating to a “market perform” rating in a research report on Friday, February 21st. Citigroup raised their target price on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, December 11th. Wells Fargo & Company reiterated an “overweight” rating and issued a $160.00 price target on shares of Integer in a research note on Tuesday, December 3rd. Benchmark increased their price target on Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Finally, KeyCorp increased their price target on Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $149.00.

Integer Stock Down 1.0 %

Shares of NYSE:ITGR opened at $115.07 on Monday. The firm has a market cap of $3.87 billion, a P/E ratio of 34.25, a P/E/G ratio of 1.72 and a beta of 1.24. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. Integer Holdings Co. has a 12-month low of $107.11 and a 12-month high of $146.36. The business has a fifty day simple moving average of $132.59 and a 200 day simple moving average of $132.38.

Integer (NYSE:ITGR) last announced its earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.46 by ($0.03). The company had revenue of $449.50 million for the quarter, compared to the consensus estimate of $446.28 million. Integer had a return on equity of 11.65% and a net margin of 6.92%. Analysts predict that Integer Holdings Co. will post 6.01 earnings per share for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.